BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 34738881)

  • 1. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
    Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
    Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
    Bao Z; Zhang W; Dong D
    Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer.
    Zhong W; Wang D; Yao B; Chen X; Wang Z; Qu H; Ma B; Ye L; Qiu J
    J Zhejiang Univ Sci B; 2021 Aug; 22(8):664-681. PubMed ID: 34414701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Tan Z; Fu S; Zuo J; Wang J; Wang H
    Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
    Front Oncol; 2023; 13():972558. PubMed ID: 37064115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
    Lu H; Wu J; Liang L; Wang X; Cai H
    Front Immunol; 2022; 13():803355. PubMed ID: 35154117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
    Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
    Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.
    Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L
    Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.
    Lai C; Wu Z; Li Z; Yu H; Li K; Tang Z; Liu C; Xu K
    Cancer Med; 2021 Sep; 10(18):6534-6545. PubMed ID: 34374227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
    Gao X; Cai J
    Front Genet; 2022; 13():865204. PubMed ID: 35571063
    [No Abstract]   [Full Text] [Related]  

  • 16. An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer.
    Lian P; Wang Q; Zhao Y; Chen C; Sun X; Li H; Deng J; Zhang H; Ji Z; Zhang X; Huang Q
    Aging (Albany NY); 2019 Sep; 11(17):6930-6940. PubMed ID: 31479417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of bladder cancer outcome by identifying and validating a mutation-derived genomic instability-associated long noncoding RNA (lncRNA) signature.
    Wu H; Zhang ZY; Zhang Z; Xiao XY; Gao SL; Lu C; Zuo L; Zhang LF
    Bioengineered; 2021 Dec; 12(1):1725-1738. PubMed ID: 33955803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic index based on a fourteen long non-coding RNA signature to predict the recurrence-free survival for muscle-invasive bladder cancer patients.
    Zhang X; Zhang M; Zhang X; Zhu X; Wang J
    BMC Med Inform Decis Mak; 2020 Jul; 20(Suppl 3):136. PubMed ID: 32646427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
    Front Immunol; 2022; 13():916800. PubMed ID: 35860239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.